{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nurix Therapeutics, Inc.
Nurix Therapeutics Hits New 52-Week High at $24.01
Nurix Therapeutics, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that surpasses the S&P 500. With a market capitalization of USD 1,518 million, the company faces challenges, including a negative return on equity and a significant debt-to-equity ratio, while operating in a competitive biotechnology landscape.
Nurix Therapeutics Hits New 52-Week High of $23.09, Up 46.61%
Nurix Therapeutics, Inc. has achieved a new 52-week high of USD 23.09, significantly up from its low of USD 8.20, reflecting a strong performance over the past year. With a market capitalization of approximately USD 1,518 million, the company remains unprofitable and has a unique financial structure.
Nurix Therapeutics Hits Day High with Strong 10.98% Intraday Surge
Nurix Therapeutics, Inc. has seen significant stock performance today, contrasting with the S&P 500's modest gains. Despite a strong weekly increase and a solid annual return, the company faces challenges, including consecutive quarterly losses and rising raw material costs, while maintaining a market capitalization of USD 1,518 million.
Is Nurix Therapeutics, Inc. technically bullish or bearish?
As of August 26, 2025, Nurix Therapeutics, Inc. is in a bearish trend with strong indicators across multiple time frames, significantly underperforming the S&P 500 with year-to-date and one-year returns of -52.39% and -63.74%, respectively.
Who are in the management team of Nurix Therapeutics, Inc.?
As of March 2022, the management team of Nurix Therapeutics, Inc. includes Dr. David Lacey (Independent Non-Executive Chairman), Dr. Arthur Sands (President and CEO), and several Independent Directors: Dr. Leon Chen, Ms. Julia Gregory, Dr. Lori Kunkel, and Dr. Jeffrey Tong. They oversee the company's strategic direction and operations.
What does Nurix Therapeutics, Inc. do?
Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapies to modulate protein levels for cancer and immune disorders. As of February 2025, it has a market cap of $868.32 million, with net sales of $18 million and a net loss of $56 million.
How big is Nurix Therapeutics, Inc.?
As of Jun 18, Nurix Therapeutics, Inc. has a market capitalization of 868.32 million, with net sales of 56.41 million and a net profit of -208.41 million over the last four quarters. The company reported shareholder's funds of 526.99 million and total assets of 675.43 million as of Nov 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
